| Company Name: | Barrier Therapeutics Inc | | Ticker Symbol: | BTRX | | | WWW Address: | www.barriertherapeutics.com | | CEO: | Alfred Altomari | | No. of Employees: | 130 | | Common Issue Type: | CS | | Business Description: | A pharmaceutical company focused on the development and commercialization of pharmaceutical products in the field of dermatology.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 0.15 |  0.0 | 0.01 | 1.01 | 0 | 4.16 | 4.14 | - |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 146.0 | 35.2 | -0.87 | -1.74 | 0.00 | 0.0 | 0.0 | 7.60 - 1.63 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 4.15 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 146.0 | mil |
| Latest Shares Outstanding | 35.2 | mil |
| Earnings pS (EPS) | -1.74 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 185,246 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 34.3 | mil |
| Float as % of Shares Outstanding | 97.4 | % |
| Foreign Sales | 0 | mil |
| Domestic Sales | 0 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 185.00 | % |
| Research & Devlopment (R&D) as % of Revenue | 88.60 | % |
| Gross Profit Margin | 91.3 | % |
| EBITDA Margin | 0.0 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 0.5 | % |
| Return on Assets (ROA) | -94.9 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -248.1 | % |
| Current Ratio | 1.5 | |
| Leverage Ratio (Assets/Equity) | 2.6 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.43 | |
| LT Debt/Total Capital | 0.0 | % |
| Working Capital pS | 0.52 | $ |
| Cash pS | 0.60 | $ |
| Book-Value pS | 0.60 | $ |
| Tangible Book-Value pS | 0.54 | $ |
| Cash Flow pS | -1.46 | $ |
| Free Cash Flow pS | -1.33 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 6.92 | |
| Price/Tangible Book Ratio | 7.69 | |
| Price/Cash Flow | -2.8 | |
| Price/Free Cash Flow | -3.1 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 0.0 | 100 | 1,489 | 4,773 |
| 4 Weeks | 4.16 | 4.10 | 4.12 | 0.7 | 99 | 1,531 | 29,097 |
| 13 Weeks | 4.16 | 1.74 | 2.37 | 75.1 | 192 | 4,914 | 304,697 |
| 26 Weeks | 4.16 | 1.63 | 3.05 | 36.1 | 143 | 3,361 | 420,078 |
| 52 Weeks | 7.60 | 1.63 | 7.20 | -42.4 | 66 | 2,018 | 504,447 |
| YTD | 4.16 | 1.63 | - | 5.3 | 122 | 2,859 | 434,572 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 4.15 | 4.14 | 3.42 | 3.16 | 3.43 | -0.87 | -1.69 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 0.00 | 0.0 | 149.17 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | -11.45 | NA | -29.23 |
| R&D | 29.95 | NA | -4.24 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 206.8 | 206.8 | 257.4 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | 0.13 | 0.13 | 0.32 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 46.04 |
| Current Ratio | 1.9 |
| Quick Ratio (Acid Test) | 1.8 |
| Liquidity Ratio (Cash) | 1.45 |
| Receivables Turnover | 3.5 |
| Average Collection Period | 103 |
| Working Capital/Equity | 91.5 |
| Working Capital pS | 0.89 |
| Cash-Flow pS | -1.51 |
| Free Cash-Flow pS | -1.38 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | -0.22 |
| Financial Leverage Ratio (Assets/Equity) | 2.0 |
| Debt Ratio | 49.7 |
| Total Debt/Equity (Gearing Ratio) | 0.26 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 0.3 |
| LT Debt/Total Liabilities | 0.3 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 0.67 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 7.11 |
| Tobin's Q Ratio | 2.16 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -2.34 |
| Enterprise Value (EV)/Free Cash Flow | -2.51 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 7.69 |
| Price/Book Ratio - LTM | 6.92 |
| Price/Cash Flow Ratio | -2.8 |
| Price/Free Cash Flow Ratio - LTM | -3.1 |
| Price/Sales Ratio | 4.94 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.00 |
| Current Liabilities pS | 0.95 |
| Tangible Book Value pS - LTM | 0.54 |
| Book Value pS - LTM | 0.60 |
| Capital Invested pS | 0.97 |
| Cash pS - LTM | 0.60 |
| Cash Flow pS - LTM | -1.46 |
| Free Cash Flow pS - LTM | -1.33 |
| Earnings pS (EPS) | -1.74 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -201.12 |
| Free Cash Flow Margin 5YEAR AVG | -2,317.14 |
| Net Profit Margin | 0.0 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | 0.71 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.71 |
| Return on Capital Invested (ROCI) | -157.8 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -113.3 |
| Assets Productivity | 0.40 |
| Return on Assets (ROA) | -79.6 |
| Return on Assets (ROA) - 5YEAR AVRG. | -57.3 |
| Gross Profit Margin | 91.3 |
| Gross Profit Margin - 5YEAR AVRG. | 0.0 |
| EBITDA Margin - LTM | 0.0 |
| EBIT Margin - LTM | 0.0 |
| Pre-Tax Profit Margin | 0.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | 1.9 |
| Effective Tax Rate - 5YEAR AVRG. | 1.3 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 323 |
| Revenue per Employee | 185,246 |
| Net Income per Employee | -413,015 |
| Average Collection Period | 176 |
| Receivables Turnover | 3.5 |
| Day's Inventory Turnover Ratio | 147 |
| Inventory Turnover | 2.5 |
| Inventory/Sales | 3.3 |
| Accounts Payble/Sales | 68.83 |
| Assets/Revenue | 2.50 |
| Net Working Capital Turnover | 0.78 |
| Fixed Assets Turnover | 8.06 |
| Total Assets Turnover | 0.4 |
| Revenue per $ Cash | 1.27 |
| Revenue per $ Plant | 36.54 |
| Revenue per $ Common Equity | 0.71 |
| Revenue per $ Capital Invested | 0.71 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 206.1 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 349.2 |
| Research & Devlopment (R&D) as % of Revenue | 115.9 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 115.9 |
|
|  
|
| |
 |  |